Revolution Medicines, Inc.
RVMD
37 insider filings · Latest: Jun 29, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | Jun 11 8:28 PM | MARGARET A HORN | Proposed Sale | 10,000 | $144.19 | $1.4M | — | View → |
| May 26, 2026 | May 28 8:10 PM | Anthony ManciniChief Global Commercialization Officer | Sale | 3,121 | $153.99 | $480.6K | 54,400(D) | View → |
| May 26, 2026 | May 26 8:46 PM | ANTHONY MANCINI | Proposed Sale | 3,121 | $151.56 | $473.0K | — | View → |
| Apr 27, 2026 | Apr 29 9:50 PM | Anthony ManciniChief Global Commercialization Officer | Sale | 3,120 | $132.41 | $413.1K | 54,400(D) | View → |
| Apr 27, 2026 | Apr 27 8:32 PM | ANTHONY MANCINI | Proposed Sale | 3,120 | $135.30 | $422.1K | — | View → |
| Apr 15, 2026 | Apr 17 11:26 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Sale | 120,000 | $150.09 | $18.0M | 276,698(D) | View → |
| Apr 15, 2026 | Apr 15 8:53 PM | MARK A GOLDSMITH | Proposed Sale | 120,000 | $147.01 | $17.6M | — | View → |
| Mar 25, 2026 | Mar 27 12:04 AM | Anthony ManciniChief Global Commercialization Officer | Sale | 37,450 | $95.56 | $3.6M | 54,400(D) | View → |
| Mar 25, 2026 | Mar 27 12:01 AM | Mancini Anthony | Proposed Sale | 37,450 | $95.56 | $3.6M | — | View → |
| Mar 17, 2026 | Mar 19 10:57 PM | Lin WeiChief Medical Officer | Sale | 2,073 | $99.48 | $206.2K | 101,366(D) | View → |
| Mar 17, 2026 | Mar 19 10:57 PM | Stephen Michael KelseyPresident, Research and Development | Sale | 4,302 | $99.48 | $428.0K | 295,398(D) | View → |
| Mar 17, 2026 | Mar 19 10:56 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Sale | 12,871 | $99.48 | $1.3M | 276,698(D) | View → |
| Mar 17, 2026 | Mar 19 10:56 PM | Margaret A HornChief Operating Officer | Sale | 4,583 | $99.48 | $455.9K | 157,570(D) | View → |
| Mar 17, 2026 | Mar 19 10:55 PM | Jack AndersChief Financial Officer | Sale | 2,753 | $99.48 | $273.9K | 125,512(D) | View → |
| Mar 19, 2026 | Mar 19 10:54 PM | Jeff CisliniGeneral Counsel | Sale | 1,163 | $97.44 | $113.3K | 58,518(D) | View → |
| Mar 17, 2026 | Mar 19 10:54 PM | Jeff CisliniGeneral Counsel | Sale | 1,795 | $99.48 | $178.6K | 59,681(D) | View → |
| Mar 17, 2026 | Mar 19 10:53 PM | Xiaolin WangEVP, Clinical Development | Sale | 2,010 | $99.48 | $200.0K | 116,063(D) | View → |
| Mar 19, 2026 | Mar 19 8:22 PM | JEFFREY TODD CISLINI | Proposed Sale | 1,163 | $98.11 | $114.1K | — | View → |
| Mar 16, 2026 | Mar 13 11:41 PM | Wang Xiaolin | Proposed Sale | 2,282 | $99.59 | $227.3K | — | View → |
| Mar 16, 2026 | Mar 13 11:40 PM | Wei Lin | Proposed Sale | 2,288 | $99.59 | $227.9K | — | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Jul 1 10:25 PM | Sushil PatelDirector | Option Exercise | 2,955 | $37.54 | 13,000(D) | View → |
| Jun 24, 2026 | Jun 26 8:10 PM | Jack AndersChief Financial Officer | Option Exercise | 20,000 | $18.56 | 20,600(D) | View → |
| Jun 18, 2026 | Jun 23 9:57 PM | Lorence H. KimDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:52 PM | Alexis BorisyDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:45 PM | Elizabeth M AndersonDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:45 PM | Sandra HorningDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:44 PM | Frank ClyburnDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:43 PM | Sushil PatelDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:42 PM | Flavia BorelliniDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 17, 2026 | Jun 17 11:51 PM | Margaret A HornChief Operating Officer | Option Exercise | 29,600 | $40.74 | 114,275(D) | View → |
| Jun 15, 2026 | Jun 17 11:51 PM | Margaret A HornChief Operating Officer | Option Exercise | 60,400 | $40.74 | 75,052(D) | View → |
| Jun 11, 2026 | Jun 15 8:05 PM | Margaret A HornChief Operating Officer | Option Exercise | 10,000 | $42.45 | 91,194(D) | View → |
| May 26, 2026 | May 28 8:10 PM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 3,121 | $33.62 | 106,109(D) | View → |
| Apr 27, 2026 | Apr 29 9:50 PM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 3,120 | $33.62 | 109,230(D) | View → |
| Apr 15, 2026 | Apr 17 11:26 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 120,000 | $4.73 | 424,085(D) | View → |
| Mar 25, 2026 | Mar 27 12:04 AM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 37,450 | $33.62 | 112,350(D) | View → |
| Mar 1, 2026 | Mar 4 2:11 AM | Xiaolin WangEVP, Clinical Development | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:10 AM | Lin WeiChief Medical Officer | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:09 AM | Stephen Michael KelseyPresident, Research and Development | Grant/Award | 47,600 | $102.02 | 47,600(D) | View → |
| Mar 2, 2026 | Mar 4 2:09 AM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 30,000 | $4.09 | 47,708(D) | View → |
Page 1 of 2
Next →